Treatment(s) already received-Biological/Targeted therapy - Page 2 of 2 Posts on Medivizor
Navigation Menu

Treatment(s) already received-Biological/Targeted therapy Posts on Medivizor

How safe and effective is the combination of ibrutinib, lenalidomide, and rituximab for relapsed or refractory mantle cell lymphoma?

Posted by on Mar 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...

Read More

Does consolidative radiotherapy improve survival in DLBCL patients?

Posted by on Feb 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the medical records of DLBCL patients who received consolidative radiotherapy (RT) after chemotherapy to determine if consolidative RT improved survival. This study concluded that consolidative RT might improve survival in DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...

Read More

Ask the Expert: Any Updates on the Use of the New Immuno-Drugs for Maintenance in Myeloma?

Posted by on Dec 8, 2017 in Multiple Myeloma | 0 comments

Video information: After receiving a successful treatment, it’s recommended that patients turn to maintenance therapy to help safeguard their quality of life and help control the residual myeloma cells from developing. The landscape for maintenance therapy continues to expand as the potential effects of new immuno-drugs emerge. Listen in as...

Read More

Review of obinutuzumab for follicular lymphoma patients who failed rituximab treatments

Posted by on Sep 23, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed the use of obinutuzumab for patients with follicular lymphoma who have failed rituximab treatment. The article concluded that obinutuzumab treatment is useful for follicular lymphoma patients who have not responded well to rituximab regimens.  Some background Follicular lymphoma (FL) is a common type...

Read More